Table of contents
April 2008 Vol 8 No 4
From the editors
p243 | doi:10.1038/nrc2370
Research Highlights
Stem cells: MicroRNAs promote differentiation | PDF (491 KB)
p245 | doi:10.1038/nrc2357
Radiation therapy: Sensitizing stem cells | PDF (106 KB)
p246 | doi:10.1038/nrc2358
Tumour suppressors: Spread your wings | PDF (164 KB)
p246 | doi:10.1038/nrc2362
In the news
Supplementary information | PDF (78 KB)
p246 | doi:10.1038/nrc2366
Metabolism: Warburg effect revisited | PDF (216 KB)
p247 | doi:10.1038/nrc2364
Metastasis: A metastatic switch | PDF (171 KB)
p248 | doi:10.1038/nrc2359
DNA repair: A major Ku? | PDF (266 KB)
p248 | doi:10.1038/nrc2360
Trial Watch
On your mind | Repairin' the brain | PDF (85 KB)
p248 | doi:10.1038/nrc2367
In brief
Tumour suppression | Tumorigenesis | Mechanotransduction | PDF (95 KB)
p249 | doi:10.1038/nrc2365
Tumorigenesis: A marked CARD | PDF (231 KB)
p250 | doi:10.1038/nrc2361
Tumorigenesis: Turning the hands of time | PDF (167 KB)
p250 | doi:10.1038/nrc2363
Drug resistance: Out on the full | PDF (253 KB)
p251 | doi:10.1038/nrc2356
Reviews
The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy
Isabel M. Chu, Ludger Hengst & Joyce M. Slingerland
p253 | doi:10.1038/nrc2347
The cyclin-dependent kinase (Cdk) inhibitor p27 regulates cell proliferation, cell motility and apoptosis, and is inactivated through various means in many types of human cancer. Recent studies in several tumour types indicate that p27 expression levels have both prognostic and therapeutic implications.
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring
Hans Lilja, David Ulmert & Andrew J. Vickers
p268 | doi:10.1038/nrc2351
Testing for prostate-specific antigen is a powerful tool in the detection of prostate cancer, but how should it be used and how can testing be improved to ensure against overdiagnosis?
GATA1-related leukaemias
Ritsuko Shimizu, James Douglas Engel & Masayuki Yamamoto
p279 | doi:10.1038/nrc2348
This Review examines whether GATA1-related leukaemias in both human and mouse can provide important insights into the mechanism of multi-step leukaemogenesis.
The distinctive biology of cancer in adolescents and young adults
Archie Bleyer, Ronald Barr, Brandon Hayes-Lattin, David Thomas, Chad Ellis, Barry Anderson & on behalf of the Biology and Clinical Trials Subgroups of the US National Cancer Institute Progress Review Group in Adolescent and Young Adult Oncology
p288 | doi:10.1038/nrc2349
One explanation for the relative lack of progress in treating cancer in adolescents and young adults is that the biology of malignant diseases in this age group is different. Do molecular, epidemiological and therapeutic outcome comparisons support this?
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Steven A. Rosenberg, Nicholas P. Restifo, James C. Yang, Richard A. Morgan & Mark E. Dudley
p299 | doi:10.1038/nrc2355
Adoptive cell therapy (ACT), using either autologous tumour-infiltrating lymphocytes or donor lymphocytes, has proved an effective treatment for some patients with advanced cancers. Can the ability to genetically engineer human lymphocytes for ACT further expand the use of this treatment?
Perspective
Opinion
Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer
Rakesh K. Jain
p309 | doi:10.1038/nrc2346
Making multidisciplinary translational clinical trials work successfully is complex and challenging. Rakesh Jain presents his perspective on the lessons he and his team have learned from two such trials in patients with advanced rectal cancer or glioblastoma.
Erratum: MYC in mammalian epidermis: how can an oncogene stimulate differentiation? (Erratum)
Fiona M. Watt, Michaela Frye & Salvador Aznar Benitah
p316 | doi:10.1038/nrc2369